Clinical Trials Browser

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03815643 2025-12-04

Avelumab Program Rollover Study

Phase 3 Active not recruiting

205 enrolled

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT05222932 2025-08-07

AVENTIL

Phase 1 Active not recruiting

15 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT05059522 2025-06-25

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

68 enrolled

Gynecologic

Ovarian Neoplasms

NCT04215146 2025-01-16

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Phase 2 Active not recruiting

48 enrolled 13 charts

Breast

Breast Neoplasms

NCT03845166 2024-11-19

STELLAR-001

Phase 1 Active not recruiting

325 enrolled

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

Clinical Trials

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Avelumab Program Rollover Study

AVENTIL

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

STELLAR-001